CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
Summary
CARsgen presented early clinical data for two allogeneic CAR T-cell candidates at EHA 2026. CT0596 showed encouraging responses in heavily pretreated relapsed/refractory multiple myeloma and primary plasma cell leukemia, with no grade 3 CRS, ICANS, or GVHD reported. CT1190B showed a 91.7% objective response rate in relapsed/refractory B-cell non-Hodgkin’s lymphoma, including activity in patients previously exposed to CAR T or bispecific antibodies. The company plans to start Phase Ib trials for both programs in 2026.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected